
Opinion|Videos|July 15, 2024
Real-World Data and Stability with Nusinersen in Adult Patients with Spinal Muscular Atrophy
Key opinion leaders address the scarcity of randomized controlled trial data for SMA treatments in adult populations, highlighting the availability of real-world data from numerous studies and provide guidance on how to incorporate this information when making treatment decisions for adult patients with spinal muscular atrophy.
Advertisement
Episodes in this series

- While we do not have randomized controlled trial data from adults for these agents, real world-data (RWD) is available from multiple studies with nusinersen (and a few with risdiplam) in adults worldwide.
- Please share your basic understanding of the RWE available for nusinersen real-world studies
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Mapping the Clinical Trial Landscape for Stem Cell Therapies in Parkinson Disease
2
What Clinicians Need to Know About Emerging Stem Cell Therapies for Parkinson Disease
3
Fenebrutinib Demonstrates Strong Efficacy, Favorable Safety in FENhance MS Trials: Jacqueline Nicholas, MD
4
Discontinuing Disease-Modifying Therapy in Older Patients With MS: John Corboy, MD
5














